Learn more about Evrysdi

Learn more about Evrysdi

Be among the first to know more about Evrysdi by signing up to receive regular updates from Genentech. A Partnership and Access Liaison (PAL) will also contact you with additional information

PALs do not provide medical advice. Your healthcare provider should always be your main resource for any questions about your health and medical care.

*Indicates a required field


Do you have a prescription for Evrysdi?*
Does the person you care for have a prescription for Evrysdi?*

I wish to receive information that may be of interest to me from Genentech and its affiliates about products, services, including co-pay assistance or other patient support, opportunities to participate in surveys or provide feedback, or other topics (including information about diseases or conditions). I may be contacted by phone, mail or email using the information I’ve provided. By asking to receive this information, I understand my personally identifiable information will be used and disclosed by Genentech, its successors, its agents, and as otherwise required by law. I understand providing this agreement is voluntary and plays no role in getting my medicine. I also understand that I may opt out of receiving this information at any time by calling 877-436-3683.

By submitting the information on this form, you agree that it will be governed by Genentech’s Privacy Policy.

Thanks for signing up!

Be on the lookout for helpful emails from us soon. To ensure you receive email communications from us, please add [email protected] to your email contact list. We look forward to being a resource for you to learn more about Evrysdi. If you have an immediate question, please reach out to a local Partnership and Access Liaison (PAL).


What is Evrysdi?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.

  • Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:
    • are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine
    • are a woman who can become pregnant:
      • Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
      • Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
    • are an adult male. Evrysdi may affect a man’s ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
    • are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby
  • Tell your healthcare provider about all the medicines you take
  • You should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement
  • Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
  • The most common side effects of Evrysdi include:
    • For later-onset SMA:
      • fever
      • diarrhea
      • rash
    • For infantile-onset SMA:            
      • fever
      • diarrhea
      • rash
      • runny nose, sneezing, and sore throat (upper respiratory infection)
      • lung infection (lower respiratory infection)
      • constipation
      • vomiting
      • cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

    • Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.

      Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.